Table 2. Uni- and multivariate analysis of predictors of SVR to antiviral therapy.
| Patient characteristics | Univariate analysis | Multivariate analysis | |||
| SVR Mean (Range) | non-SVR Mean (Range) | p-value | OR (95% CI) | p-value | |
| Age (years) | 42 (18–68) | 46 (19–70) | <0.001 | 1.029 (1.002–1.057) | 0.032 |
| Sex (female/male) *n, [%] | 106* [26,6%]/111*[27,8%] | 76* [19,0%]/104* [26,1%] | 0.1 | ||
| BMI (kg/m2) | 24.7 (17.3–45.5) | 24.7 (16.6–42.9) | 0.5 | ||
| ALT_fact (times upper limit of normal, IU/l) | 1.64 (0.31–9.8) | 1.56 (0.36–12.8) | 0.4 | ||
| AST_fact (times upper limit of normal, IU/l) | 1.09 (0.43–7.96) | 1.1 (0.48–7.89) | 0.3 | ||
| GGT_fact (times upper limit of normal, IU/l) | 0.71 (0.15–7.31) | 1.28 (0.25–16.08) | <0.001 | 1.46 (1.068–1.995) | 0.017 |
| HOMA-index | 1.75 (0.3–20) | 2.55 (0.1–22.6) | <0.001 | 0.949 (0.87–1.036) | 0.2 |
| Cholesterol (mg/dl) | 182 (101–320) | 166.2 (61–289) | <0.001 | 0.983 (0.975–0.991) | <0.001 |
| Triglyceride (mg/dl) | 89 (25–422) | 93 (16–490) | 0.7 | ||
| AP (IU/l) | 65 (32–181) | 71.5 (32–204) | <0.001 | 1.011 (0.997–1.026) | 0.09 |
| Ferritin (µg/l) | 101 (3.7–780) | 153 (6–1846) | <0.001 | 1.002 (1.000–1.004) | 0.032 |
| Vitamin D baseline (ng/ml) | 15.8 (3–76.2) | 17.6 (3.1–84.3) | 0.09 | ||
| Vitamin D TW 24 (ng/ml) | 16.7 (3.7–56.9) | 16.35 (3.2–61.9) | 0.5 | ||
| IP10 baseline (pg/ml) | 228 (58.4–2000) | 279 (41.2–2000) | 0.009 | 1.000 (0.999–1.001) | 0.2 |
| TSH (µIU/ml) | 1.37 (0.02–12) | 1.24 (0.01–5.03) | 0.2 | ||
| IL28B-rs12979860 (CC/non_CC) | 85 [23,1%]/32 [8,79%] | 118 [32,1%]/132 [35,9%] | <0.001 | 2.476 (1.289–4.757) | 0.006 |
| CYP27B1-rs10877012 (AA/non_AA) | 27 [7,3%]/176 [48,0%] | 12 [3,29%]/151 [41,2%] | 0.06 | ||
| CYP2R1- rs10741657 (AA/non_AA) | 33 [9,0%]/170 [46,4%] | 18 [4,9%]/145 [39,6%] | 0.1 | ||
| DHCR7-rs12785878 (TT/non_TT) | 100 [26,6%]/109 [29%] | 98 [26,1%]/68 [18,1%] | 0.031 | 0.745 (0.417–1.331) | 0.3 |
| CYP24A1-rs6013897 (TT/non_TT) | 128 [34,1%]/81 [21,6%] | 104 [27,7%]/62 [16,5%] | 0.7 | ||
| DHCR7-rs7944926 (GG/non_GG) | 106 [28,2%]/103 [27,4%] | 98 [26,1%]/68 [18,1%] | 0.1 | ||
| DBP-rs2282679 (TT/non_TT) | 111 [29,6%]/98 [26], [1] | 85 [22,6%]/81 [21,6%] | 0.7 | ||
| DBP-rs4588 (CC/non_CC) | 107 [28,5%]/102 [27,2%] | 81 [21,6%]/85 [22,6%] | 0.6 | ||
| DBP-rs7041 (GG/non_GG) | 65 [17,3%]/144 [38,4%] | 50 [13,3%]/116 [30,9%] | 0.8 | ||
| Fibrosis stage (0–2/3–4) | 184 [48,6%]/19 [5,0%] | 137 [43,0%]/38 [10,0%] | <0.001 | 1.489 (0.562–3.946) | 0.4 |
Only patients with complete data for the remaining covariates (277 out of 398) and with significant variations in the univariate analysis were included in multivariate analyses. Missing data and abbreviations are illustrated in the legend of Table 1. A VitD deficiency (<20 ng/ml) was observed in 251 (64,1%) out of 391patients. A liver fibrosis stage of 0–2 was observed in 321 (84,9%) out of 378 patients, while 57 (15%) out of 378 patients showed a liver fibrosis stage of 3–4.